Dharmacon has recently introduced the miRidian microRNA inhibitors and mimics.
According to the company, the inhibitors and mimics are based on known or predicted miRNA sequences for human, mouse and rat as defined in the Wellcome Trust Sanger Institute's miRBase.
MiRNA inhibitors facilitate loss-of-function studies, while miRNA mimics may be useful for gain-of function studies, Dharmacon said.
NOTE: This is the last issue of RNAi News to be published in 2005. We will resume our normal publishing schedule on Jan. 6, 2006.